INRLF (Valneva SE) Total Liabilities : $332.0 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Valneva SE Total Liabilities?

Valneva SE's Total Liabilities for the quarter that ended in Sep. 2024 was $332.0 Mil.

Valneva SE's quarterly Total Liabilities declined from Mar. 2024 ($340.87 Mil) to Jun. 2024 ($323.24 Mil) but then increased from Jun. 2024 ($323.24 Mil) to Sep. 2024 ($332.01 Mil).

Valneva SE's annual Total Liabilities declined from Dec. 2021 ($730.82 Mil) to Dec. 2022 ($425.37 Mil) and declined from Dec. 2022 ($425.37 Mil) to Dec. 2023 ($361.85 Mil).

Valneva SE Total Liabilities Historical Data

The historical data trend for Valneva SE's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Total Liabilities Chart

Valneva SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

143.97

452.24

730.82

425.37

361.85

Valneva SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															387.43	361.85	340.87	323.24	332.01

Valneva SE Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Valneva SE's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	173.242	+	(176.508	+	8.131
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	3.967	+	0)
	=	361.8

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	501.703	-	139.855
	=	361.8

Valneva SE's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	121.15	+	(198.825	+	7.831
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	4.208	+	0)
	=	332.0

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	573.378	-	241.364
	=	332.0

Valneva SE Total Liabilities Related Terms

Thank you for viewing the detailed overview of Valneva SE's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

VALN:USA VLAp:UK 0OB3:UK VLA:France AYJ:Germany AYJ:Bulgaria VLA:Austria

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.